419 related articles for article (PubMed ID: 29407597)
1. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies.
Gragnano F; Calabrò P
Atherosclerosis; 2018 Feb; 269():219-228. PubMed ID: 29407597
[TBL] [Abstract][Full Text] [Related]
2. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
4. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
5. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
[TBL] [Abstract][Full Text] [Related]
6. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
[TBL] [Abstract][Full Text] [Related]
7. Lipid management in ACS: Should we go lower faster?
Gencer B; Mach F
Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
9. Poststatin Lipid Therapeutics: A Review.
Jia X; Lorenz P; Ballantyne CM
Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
[TBL] [Abstract][Full Text] [Related]
10. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
11. Implications for REDUCE IT in clinical practice.
Bittner V
Prog Cardiovasc Dis; 2019; 62(5):395-400. PubMed ID: 31715195
[TBL] [Abstract][Full Text] [Related]
12. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
13. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
[TBL] [Abstract][Full Text] [Related]
14. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
15. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
16. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
[TBL] [Abstract][Full Text] [Related]
17. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
Hollstein T; Vogt A; Grenkowitz T; Stojakovic T; März W; Laufs U; Bölükbasi B; Steinhagen-Thiessen E; Scharnagl H; Kassner U
Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
[TBL] [Abstract][Full Text] [Related]
18. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
Adhyaru BB; Jacobson TA
Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
20. LDL cholesterol: How low to go?
Packard CJ
Trends Cardiovasc Med; 2018 Jul; 28(5):348-354. PubMed ID: 29336946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]